The regulatory position at a glance
Semaglutide is the active ingredient in two families of branded medicines: Ozempic and Rybelsus (both authorised in the UK for type 2 diabetes management), and Wegovy (authorised specifically for chronic weight management at a higher concentration). This article focuses on the Wegovy authorisations, as they concern the weight-management indication that drives most public interest in the UK.
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK's competent authority for human medicines. Since the UK's departure from the EU regulatory framework, it is the MHRA — not the European Medicines Agency — that determines whether a medicine is legally authorised for supply in Great Britain. Northern Ireland has distinct arrangements under the Windsor Framework, where EU pharmaceutical law continues to apply in some circumstances.
Prescription-only medicine (POM). Legal to supply in the UK only on a valid prescription from a registered prescriber.
First oral semaglutide product authorised in Europe for weight management. Prescription-only. NHS access pending NICE review at time of publication.
Injectable Wegovy: what the MHRA authorisation means in practice
The MHRA granted a marketing authorisation for injectable Wegovy (semaglutide 2.4 mg per dose, delivered via a pre-filled auto-injector pen) for use in chronic weight management in adults who meet specified clinical criteria. That authorisation classifies it as a prescription-only medicine under Schedule 1 of the Human Medicines Regulations 2012.
The practical consequence is unambiguous: injectable Wegovy can only be lawfully supplied in the UK when a registered prescriber — a doctor, nurse prescriber, or pharmacist prescriber — has assessed a patient and issued a prescription. A registered pharmacy then dispenses against that prescription under a well-defined contractual and regulatory framework. There is no legal route by which a consumer can obtain an authorised injectable semaglutide product without a prescription from a person regulated by the General Medical Council, the Nursing and Midwifery Council, or another relevant competent professional body.
This classification also means that the product's quality, safety, and efficacy have been assessed by MHRA scientists using clinical trial data submitted by the manufacturer. The Certificate of Analysis tied to each authorised batch must comply with the specifications in the marketing authorisation — a substantially higher and more rigorously enforced standard than anything applied to unlicensed products. That traceability between each released batch and its documented quality testing is what separates an authorised medicine from an online powder.
Oral Wegovy: the June 2026 milestone
In June 2026, the MHRA granted marketing authorisation to oral Wegovy — a semaglutide tablet formulation — making the UK the first country in Europe to authorise an oral form of semaglutide specifically for weight management. This followed earlier approvals in other jurisdictions for diabetes-related semaglutide tablet formulations.
The authorisation of an oral form is significant for several reasons. It widens the potential patient population, since injectable medicines are a practical or psychological barrier for some people. It also sharpens the regulatory boundary in a consequential way: a legitimate oral semaglutide product now exists inside the licensed framework, which means that drops, solutions, and other oral preparations sold outside that framework have no claim to any form of regulatory recognition — not even the argument that no oral alternative exists.
Like injectable Wegovy, the oral tablet is classified as a prescription-only medicine. It cannot be legally supplied without a prescription from a registered UK prescriber. An authorised product sold by a regulated pharmacy against a valid prescription is legally and qualitatively distinct from any unlicensed oral semaglutide preparation sold online.
NHS access and the NICE review
Holding an MHRA marketing authorisation is not the same as being routinely funded by the National Health Service. For a medicine to be prescribed at NHS expense in England, it generally requires a positive recommendation from the National Institute for Health and Care Excellence (NICE), which conducts a health technology appraisal weighing clinical benefit against cost-effectiveness.
NICE issued guidance on injectable Wegovy for weight management via Technology Appraisal TA875, recommending it for use within specialist weight management services for adults who meet defined clinical thresholds. NHS implementation has been phased, partly due to global supply constraints affecting semaglutide products.
At the time of publication, NHS-funded access to the oral Wegovy formulation was pending a separate NICE technology appraisal. Patients seeking access before that review concludes would need to explore private prescription routes through a registered UK prescriber. Neither route involves obtaining semaglutide from an unlicensed source — the authorised product is the only legally valid option in both cases.
What the Human Medicines Regulations 2012 say about unlicensed products
The Human Medicines Regulations 2012 is the primary legislative instrument governing the manufacture, authorisation, and supply of medicines in the UK. Under this framework, a medicinal product intended for human use requires either a marketing authorisation, a traditional herbal registration, or another specific licence before it can be sold or supplied commercially. There are narrow exemptions — for example, a registered pharmacist may supply an unlicensed medicine to meet the specific need of a particular patient on a prescriber's written request — but these provisions are tightly controlled and do not extend to general online commercial sale.
Semaglutide products sold online that carry no MHRA marketing authorisation number sit entirely outside this framework. This category includes:
- Semaglutide powders marketed as research chemicals or peptides intended for reconstitution
- Oral drops or solutions described as containing semaglutide but without any MHRA authorisation
- Transdermal patches claiming to deliver semaglutide through the skin
- Nasal sprays or other novel delivery formats with no regulatory approval in the UK
None of these product types hold an MHRA marketing authorisation. Supplying them commercially in the UK for human use is an offence under the Regulations. The absence of regulatory oversight means there is no independent verification of what these products actually contain, in what concentration, or under what manufacturing conditions they were produced. That is precisely the gap that a genuine Certificate of Analysis — issued under an authorised manufacturing and quality framework — is designed to close. A COA from a seller of unlicensed material cannot replicate that framework.
MHRA enforcement: the 20 million dose signal
The MHRA's enforcement activity in this space has grown substantially as the market for weight-loss medicines has expanded. In 2025, the agency reported seizing approximately 20 million doses of unlicensed weight-loss products as part of coordinated operations targeting online supply chains and importers. That figure conveys both the scale of the unlicensed market and the seriousness with which the regulator is treating it.
Enforcement action can be directed at importers, fulfilment businesses, online platforms, and individuals who supply unlicensed medicines commercially. The MHRA has powers under the Human Medicines Regulations 2012 to seize goods, pursue prosecutions, and seek injunctions preventing continued supply. Persons found to have commercially supplied unlicensed medicines face criminal liability.
The 20 million dose figure is also a signal about quality risk that sits upstream of any legal question. These are not products that failed MHRA testing — they are products that were never submitted for testing under any accredited framework. Their identity, purity, and safety profile are unknown in the absence of independent laboratory verification. Any document attached to such a product and styled as a Certificate of Analysis is a commercial assertion, not a regulatory or independently verified quality record.
Any semaglutide product sold online without an MHRA marketing authorisation number — regardless of whether it is described as a research chemical, a peptide, a supplement, or an alternative formulation — is an unlicensed medicine under UK law. No Certificate of Analysis issued by its seller substitutes for the independent regulatory assessment that an authorised medicine has undergone before supply.
Why the authorisation boundary matters for quality documentation
The connection between regulatory authorisation and quality documentation is direct and not accidental. An MHRA-authorised medicine's manufacturing process is described in a Marketing Authorisation dossier lodged with the regulator. Each batch must be independently tested and formally released against the approved specification before it may enter supply. The Certificate of Analysis for an authorised batch has legal standing: it must accurately reflect test results obtained using validated methods, or the issuer faces regulatory and criminal liability.
For unlicensed products, there is no such framework. A seller can produce any document and call it a Certificate of Analysis. Without the background of a regulatory submission, an accredited manufacturing site, and an independent laboratory operating within a licensed supply chain, the document proves nothing verifiable about the material in a vial or sachet. Understanding the MHRA authorisation boundary is therefore simultaneously a legal question and a quality question. The two cannot be separated here: the legal status of a semaglutide product in the UK is the clearest indicator of whether its quality documentation rests on independently verified science or on an unverified commercial claim.
Disclaimer: This article is an educational overview of publicly available regulatory information. It does not constitute legal advice, medical advice, or a recommendation to use any product. Regulatory positions can change; consult the MHRA's official publications and a qualified healthcare professional or solicitor for current, case-specific guidance. Get the COA does not sell products and does not give medical advice.
Sources: Human Medicines Regulations 2012 (legislation.gov.uk) · MHRA (gov.uk) · NICE TA875 — semaglutide for weight management · EMA — Wegovy EPAR. Information only. Updated 17 July 2026.